www.takeda.com
Takeda
The four-year collaboration between Evotec and Takeda (see press release of 1 August 2003) is aimed at jointly identifying and validating novel targets relating to different aspects of the causes and progression of Alzheimer's disease, with the goal of developing innovative small molecule therapeutics. Total payments to Evotec will reach up to EUR 20 million covering access fees to Evotec's proprietary database of Alzheimer's disease-related targets, research funding and success based milestone payments relating to the selection of targets for further drug discovery. Additional substantial milestones would also be payable on the successful clinical development of compounds acting on selected targets.
"We are very much excited to enter into this collaboration with Evotec Neurosciences. In choosing this partnership, we expect to be able to make full use of the valuable database to accelerate our research for the creation of new drugs for Alzheimer's disease. Takeda is pursuing every possibility for enhancing its R&D pipeline, and promoting actively alliances with our partners so that we can utilize outside resources efficiently in our research."
Takashi Soda, Ph.D., General Manager, Research Division, Takeda